Fundraising Fox
Cyclarity
Novato, US · Founded 2019 · 19 employees on LinkedIn · 2 known investors
Find your way into Cyclarity
Sign up to see every warm intro you have to Cyclarity
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cyclarity team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cyclarity Therapeutics develops engineered cyclodextrin drugs that target and remove toxic oxidized cholesterol (7-ketocholesterol) to treat atherosclerosis and other age-related diseases. Its lead candidate, UDP-003, is a preclinical/early clinical therapy aimed at cardiovascular disease, with additional pipeline programs for stroke recovery, Alzheimer's, and other conditions.
Founders & leadership
Cyclarity was founded in 2019 by Matthew O'Connor and Amelia Anderson.
Investors · 2
How we know: Seed Healthcare's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$15.3M disclosed across 3 rounds · 2019–2024
▶$10.3MraisedDec 2024 · 19 investors · PharmaceuticalsRule 506(b)
- Matthew O'ConnorExecutive Officer, Director
- Michael KopeExecutive Officer, Director
- Offering amount
- $12.8M
- Amount sold
- $10.3M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedSep 2021 · 10 investors · PharmaceuticalsRule 506(b)
- Matthew O'ConnorExecutive Officer, Director
- Frank SchuelerDirector
- Michael KopeExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $3.5M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedNov 2019 · 9 investors · PharmaceuticalsRule 506(b)
- Matthew O'ConnorExecutive Officer, Director
- Frank SchuelerDirector
- Michael KopeExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.5M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Cyclarity went on to found or lead other companies.
In the news
Frequently asked questions
- What does Cyclarity do?
- Cyclarity Therapeutics develops engineered cyclodextrin drugs that target and remove toxic oxidized cholesterol (7-ketocholesterol) to treat atherosclerosis and other age-related diseases. Its lead candidate, UDP-003, is a preclinical/early clinical therapy aimed at cardiovascular disease, with additional pipeline programs for stroke recovery, Alzheimer's, and other conditions.
- Who founded Cyclarity?
- Cyclarity was founded by Matthew O'Connor, Amelia Anderson in 2019.
- Who are Cyclarity's investors?
- Cyclarity's investors include Seed Healthcare, Formic Ventures.
- How much funding has Cyclarity raised?
- Cyclarity has disclosed $15.3M raised across 3 rounds.
- Where is Cyclarity headquartered?
- Cyclarity is headquartered in Novato, US.